Avant View

AVANT VIEW Quarterly Report Q3 2025

The life sciences industrial sector navigated a quarter of significant strategic consolidation in Q3 2025, marked by several large acquisitions that reshaped competitive landscapes across R&D software, bioprocessing, and drug delivery technologies.

Following Q2’s measured momentum, the third quarter saw accelerated M&A activity as strategic acquirers moved decisively to strengthen their technology portfolios and expand market positions.

Siemens completed its $5.1 billion acquisition of Dotmatics in July, Thermo Fisher completed its acquisition of Solventum’s purification and filtration business for $4.0 billion in September (Top stories below), and Halozyme Announced its Acquisition of Elektrofi for up to $900 million, combining complementary subcutaneous drug delivery platforms. This creates a strong signal for drug delivery technologies and positive tailwinds for portfolio companies like Intrepid Labs.

Deals:

On the venture side, Q3 re-iterated the robust appetite for AI-driven platforms across the value chain with a few large deals, while the broader funding market remained more measured overall.

Lila Sciences announced the first tranche of its Series A, raising $235 million in September. Lila’s massive round reflects the extraordinary hype around AI and “scientific superintelligence.”, with big funding and still lots to prove.

Chai Discovery raised $70 million in Series A funding. The round followed the company’s breakthrough Chai-2 model release, which achieved a near 20% hit rate in fully de novo antibody design dramatically outperforming traditional lab methods.

Enveda Biosciences raised $150 million in an oversubscribed Series D in September. With proprietary data feeding into a unique platform driving a robust pipeline, Enveda exemplifies the sustained investor interest in AI-powered natural product drug discovery.

AVANT VIEW

The U.S. Gains as the U.K. Loses BioPharma Investment Ground

In our last quarterly report, we highlighted substantial, multi-year capital commitments across the industry to expand U.S. operations in response to mounting tariff pressures and supply chain vulnerabilities. Roughly $168 billion in commitments were made by Amgen, Eli Lilly, Gilead, Johnson & Johnson, Novartis, Roche, Sanofi, Takeda, and Thermo Fisher Scientific combined. The list has grown now to include Pfizer’s $70 billion dedicated to U.S. research, development and capital projects in the next few years. GSK plans to invest $30 billion in R&D and Manufacturing in the United States over next 5 years. Whether these announced investments are just signals to appease current administration policy or will fully materialize remains to be seen.

Meanwhile the UK is experiencing quite a different story as several announcements of reduced investments sighting the “UK not making meaningful progress towards addressing the lack of investment in the life science industry and the overall undervaluation of innovative medicines and vaccines by successive UK governments.” Nearly $2.5B in planned investments have been stalled or cancelled.  Notably Merck announced it was scrapping research operations in London, AstraZeneca has paused a planned $270M investment in its Cambridge, and Eli Lilly is reconsidering its UK biotech incubator buildout.

Top Stories

Thermo Fisher Bolsters Bioprocessing Arsenal Completing $4.1B Solventum Filtration Deal

Thermo Fisher Scientific has completed its acquisition of Solventum’s Purification & Filtration business, integrating it into its Life Sciences Solutions segment to strengthen its bioprocessing footprint. The acquired unit, responsible for ~$1 billion in 2024 revenue, adds critical filtration and membrane technologies across upstream/downstream workflows and adjacent industrial markets. Thermo Fisher expects to realize $125 million of adjusted operating income through synergies by year five, this move underscores the ongoing consolidation in biopharma tools and signals Thermo’s bid to own more of the end-to-end biologics manufacturing chain.

Consolidation Accelerates as Waters Expands into Regulated Diagnostics Through BD Merger

Waters Corporation and BD’s Biosciences & Diagnostic Solutions are combining Waters with BD’s Biosciences & Diagnostic Solutions unit in a $17.5 billion Reverse Morris Trust (RMT) transaction, creating a new life sciences / diagnostics leader focused on regulated high-volume testing. The deal effectively doubles Waters’ total addressable market to ~$40 billion and results in a business model with over 70% recurring revenue. Pro forma 2025 revenues are expected at ~$6.5 billion with adjusted EBITDA of ~$2.0 billion, and the companies anticipate ~$345 million in annual synergies by 2030. This tie-up signals a major consolidation and escalation in the biopharma tools & diagnostics space.

Siemens Completes $5.1 Billion Acquisition of Dotmatics to Expand Life Sciences Software Portfolio

Siemens has completed its acquisition of Dotmatics, a life sciences R&D software company, for an enterprise value of $5.1 billion, expanding its AI-powered Product Lifecycle management portfolio to create an end-to-end digital thread connecting research data through to manufacturing. It’s expected to add $300M+ in revenue for fiscal 2025. Dotmatics will become part of Siemens’ Digital Industries Software business, expanding Siemens’ AI-powered PLM (Product Lifecycle Management) offerings into the life sciences sector, it’s expected to add $300M+ in revenue for fiscal 2025

Industry News

Alpenglow Biosciences and Virdx Announce Strategic Deal to Advance AI-Enabled Prostate Cancer Diagnostics

RoosterBio & Secretome Therapeutics Announce Successful Completion of Large-Scale Bioreactor Production for Clinical Stage Cell Therapy Candidate

NIH Announces End to Funding of new grants for animal-only studies

The looming patent cliff puts $180bn in Pharma Sales at Risk in 2027 and 2028

BioLife Solutions Makes $2M Strategic Investment in Pluristyx

Evotec and Sandoz deal will enable Sandoz to produce biosimilar medicines using Just – Evotec Biologics’ Advanced Continuous Manufacturing Technology

Thermo Fisher will acquire Sanofi’s US-based State-of-the-art Sterile Fill-Finish and Packaging Facility

FDA removes CAR-T Risk Evaluation and Mitigation Strategies (REMS) to boost cancer immunotherapy uptake

$81M Tempus – Paige deal signals further consolidation in digital pathology market

FDA Waives Clinical Efficacy Studies (CESs) for monoclonal antibody biosimilars significantly reducing development costs and accelerate approval timelines

Fluidic Sciences Acquires Sphere Bio to Accelerate Single‑Cell and Protein Interaction Discovery